The Latest Breaking News from Zoetis

Zoetis has significantly underperformed the broader market over the past year, yet analysts remain bullish on the stock’s prospects.

Zoetis beat third-quarter expectations and raised its outlook for the year. But Zoetis stock slipped early Monday.

Zoetis (ZTS) continues to showcase its solid market position and commitment to innovation across its diverse portfolio, introducing advanced products that meet the evolving needs of animal health. Given its robust fundamentals and industry leadership, let’s find out if ZTS is a solid choice for those looking to invest in…

Despite Zoetis lagging behind the broader market over the past year, analysts still remain strongly bullish on the stock’s prospects.

Zoetis stock surged Tuesday on strong second-quarter sales for companion and livestock sales, and after hiking its outlook for 2024.

As Zoetis is all set to announce its second-quarter earnings next month, analysts project a single-digit improvement in its bottom line.

The pet care industry’s robust expansion is driven by rising disposable income, adoption of e-commerce platforms, and rising pet ownership. Therefore, investors could consider watching fundamentally sound pet care stocks, Zoetis (ZTS), IDEXX Laboratories (IDXX), and Chewy (CHWY). Keep reading.

Amid a broader market rotation out of Big Tech stocks, investors can consider these three top-rated healthcare stocks with double-digit upside potential.

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, favorable R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks Zoetis (ZTS), Viatris (VTRS), and Bristol-Myers Squibb (BMY) poised for blockbuster return potential. Keep reading….